Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
VEGF
Fierce Biotech
AstraZeneca scales Summit’s PD-1xVEGF combos with $2B investment
AstraZeneca is investing $2 billion in Summit to accelerate the development of PD-1xVEGF bispecific ivonescimab in combination with ADCs.
Nick Paul Taylor
Sep 29, 2026 3:07am
After 3 CRLs, FDA approves Outlook's AMD drug Lytenava
Jul 27, 2026 11:51am
Akeso, Summit's ivonescimab ups PD-1 in chemo combo in 1L NSCLC
Oct 19, 2025 10:45am
Editor's Corner—Summit must submit to Big Pharma, stat
Sep 10, 2025 2:50pm
Merck CMO talks Akeso, Summit's Keytruda head-to-head win
Jun 3, 2024 12:00pm
Summit and Akeso deliver Keytruda-topping results in NSCLC
May 31, 2024 11:00am
